Zag Bio
Last verified 2026-05-14. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $100.0Mattributed |
|---|---|
| Latest round | series-a, $80.0M, 2025-10-28attributed |
| Founded | 2022 |
| Headquarters | Cambridge, MA |
| Industry | biotech |
| Stage | series-a |
| Website | zagbio.com |
Zag Bio develops bifunctional antibodies that ferry self-antigens to the thymus to retrain T cells and restore natural immune tolerance instead of suppressing immunity broadly. It targets patients with autoimmune diseases starting with type 1 diabetes via lead program ZAG-101. Acting in the thymus, the only site of central T-cell tolerance, gives the platform a durable mechanism.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-10-28 | series-a | $80.0M | undisclosed |
Detected tech stack
Cloudflare, WordPress, Yoast SEO 26.6, Google Analytics, Google Hosted Libraries, Google Tag Manager, Slick, jQuery Migrate 3.4.1, DoubleClick Floodlight, cdnjs, Cloudflare Bot Management, Vercel Speed Insights
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $80.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $100.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | zagbio.com, read 2026-05-14 |
| Description | self-reported | zagbio.com, read 2026-05-14 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.